Ferinject® 50 mg ironmL solution for injectioninfusion

Nchi: Malesia

Lugha: Kiingereza

Chanzo: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
03-05-2019
Tabia za bidhaa Tabia za bidhaa (SPC)
11-01-2022

Viambatanisho vya kazi:

Ferric Carboxymaltose

Inapatikana kutoka:

ZUELLIG PHARMA SDN BHD

INN (Jina la Kimataifa):

Ferric Carboxymaltose

Vitengo katika mfuko:

10 ml; 20 ml

Viwandani na:

IDT BIOLOGIKA GMBH

Taarifa za kipeperushi

                                Not Applicable
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                200716_SPC-YV007/YV080/YV013/MR/E30 T UK01-MY
1/10
1.
NAME OF THE MEDICINAL PRODUCT
Ferinject 50 mg iron/mL solution for injection/infusion.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One mL of solution contains 50 mg of iron as ferric carboxymaltose.
Each 10 mL vial contains 500 mg of iron as ferric carboxymaltose.
Each 20 mL vial contains 1,000 mg of iron as ferric carboxymaltose.
Excipient(s) with known effect
One mL of solution contains up to 5.5 mg (0.24 mmol) sodium, see
section 4.4.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection/infusion. Dark brown, non-transparent, aqueous
solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Ferinject is indicated for the treatment of iron deficiency when (see
section 5.1):
–
oral iron preparations are ineffective.
–
oral iron preparations cannot be used.
–
there is a clinical need to deliver iron rapidly.
The diagnosis of iron deficiency must be based on laboratory tests.
[e.g., plasma ferritin levels,
haemoglobin, haematocrit, red cell count, MCV, MCH and transferrin
saturation (TSAT).]
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Monitor carefully patients for signs and symptoms of hypersensitivity
reactions during and following
each administration of Ferinject.
Ferinject should only be administered when staff trained to evaluate
and manage anaphylactic
reactions is immediately available, in an environment where full
resuscitation facilities can be
assured. The patient should be observed for adverse effects for at
least 30 minutes following
each Ferinject administration (see section 4.4).
Posology
The posology of Ferinject follows a stepwise approach: [1]
determination of the individual iron need,
[2]
calculation and administration of the iron dose(s), and [3] post-iron
repletion assessments. These
steps are outlined below:
_Step 1: Determination of the iron need _
The individual iron need for repletion using Ferinject is determined
based on the patient’s body weight
and haemoglobin (Hb) level. Refer to T
                                
                                Soma hati kamili